WallStreetZenWallStreetZen

NASDAQ: HCM
Hutchmed Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their HCM stock forecasts and price targets.

Forecast return on equity

Is HCM forecast to generate an efficient return?

Company
329.17%
Industry
44.89%
Market
80.85%
HCM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HCM forecast to generate an efficient return on assets?

Company
196.32%
Industry
15.31%
HCM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HCM earnings per share forecast

What is HCM's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.43+612.5%
Avg 2 year Forecast
$1.00+401.65%
Avg 3 year Forecast
$2.08+940%
HCM's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

HCM revenue forecast

What is HCM's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$680.1M+7.92%
Avg 2 year Forecast
$820.4M+30.18%
Avg 3 year Forecast
$959.8M+52.3%
HCM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HCM earnings growth forecast

How is HCM forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
95.74%
Industry
22.89%
Market
17.6%
HCM's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
HCM's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
HCM's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

HCM revenue growth forecast

How is HCM forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
15.06%
Industry
4.39%
Market
10.18%
HCM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HCM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HCM vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
HCM$15.16N/AN/A
AMRX$7.75$11.33+46.23%Strong Buy
ALVO$7.86N/AN/A
BHC$5.51$9.00+63.34%Hold
SUPN$32.49$36.00+10.80%Hold
View Top Pharmaceutical Stocks

Hutchmed Stock Forecast FAQ

What is HCM's earnings growth forecast for 2025-2027?

(NASDAQ: HCM) Hutchmed's forecast annual earnings growth rate of 95.74% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 22.89%, and it is also forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Hutchmed's earnings in 2025 is $37,729,000.On average, 4 Wall Street analysts forecast HCM's earnings for 2025 to be $1,242,031,560, with the lowest HCM earnings forecast at $52,296,066, and the highest HCM earnings forecast at $2,649,667,329. On average, 3 Wall Street analysts forecast HCM's earnings for 2026 to be $874,477,379, with the lowest HCM earnings forecast at $758,292,953, and the highest HCM earnings forecast at $1,080,785,358.

In 2027, HCM is forecast to generate $1,812,930,278 in earnings, with the lowest earnings forecast at $1,812,930,278 and the highest earnings forecast at $1,812,930,278.

If you're new to stock investing, here's how to buy Hutchmed stock.

What is HCM's revenue growth forecast for 2025-2027?

(NASDAQ: HCM) Hutchmed's forecast annual revenue growth rate of 15.06% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.

Hutchmed's revenue in 2025 is $630,201,000.On average, 3 Wall Street analysts forecast HCM's revenue for 2025 to be $592,787,235,524, with the lowest HCM revenue forecast at $541,473,464,258, and the highest HCM revenue forecast at $640,015,812,457. On average, 2 Wall Street analysts forecast HCM's revenue for 2026 to be $715,059,795,136, with the lowest HCM revenue forecast at $699,634,198,957, and the highest HCM revenue forecast at $730,485,391,315.

In 2027, HCM is forecast to generate $836,562,730,981 in revenue, with the lowest revenue forecast at $836,562,730,981 and the highest revenue forecast at $836,562,730,981.

What is HCM's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: HCM) forecast ROA is 196.32%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.31%.

What is HCM's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: HCM) Hutchmed's current Earnings Per Share (EPS) is $0.20. On average, analysts forecast that HCM's EPS will be $1.43 for 2025, with the lowest EPS forecast at $0.06, and the highest EPS forecast at $3.04. On average, analysts forecast that HCM's EPS will be $1.00 for 2026, with the lowest EPS forecast at $0.87, and the highest EPS forecast at $1.24. In 2027, HCM's EPS is forecast to hit $2.08 (min: $2.08, max: $2.08).

What is HCM's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: HCM) forecast ROE is 329.17%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.